Citi analyst Yigal Nochomovitz lowered the firm’s price target on Lenz Therapeutics (LENZ) to $26 from $52 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Buy Rating on VIZZ Underscored by Improving Prescription Trends and Long-Term Upside Despite Near-Term Revenue Revisions
- Lenz Therapeutics price target lowered to $29 from $35 at BofA
- Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)
- Is LENZ a Buy, Before Earnings?
- Lenz Therapeutics announces submission of MAA to EMA for VIZ